Modus Therapeutics Holding Ab · OMXSTO:MODTX
Modus Therapeutics Holding Ab — Q2 2024 Earnings Presentation
25 slides from Modus Therapeutics Holding Ab's earnings presentation, Aug 22, 2024
Slide 1: Modus Therapeutics Interim Report for the Second Quarter 2024
MODUS THERAPEUTICS INTERIM REPORT FOR THE SECOND QUARTER 2024 January - June 2024 1
Slide 2: The Quarter in Brief
THE QUARTER IN BRIEF | JANUARY 1 - JUNE 30 2O24 Interim report for the second quarter 2024 The second quarter in figures • The loss per share amounted to SEK 0,22 (0,67). Important events after the end of the period • The loss after tax amounted to TSEK 4 738 (4 • The cash flow from current operatio
Slide 3: CEO Statement: Anemia study in kidney failure awaiting final approval
CEO STATEMENT Anemia study in kidney failure awaiting final approval The quarter was characterized by continued intensive work on Modus’ prioritized phase IIa study to establish proof-of-concept for the treatment effect of sevuparin in patients with anemia in chronic kidney disease. The study is now
Slide 4: CEO Statement
CEO STATEMENT and severe malaria, are progressing with pre- ch.org/articles/8-484). We look forward to the second half of the paratory work for planned clinical trials. For year where continued updates on the anemia sepsis, it is still essential to continue publish Sepsis and kidney failure highligh
Slide 5: About Modus Therapeutics
STATEMENT OF OPERATIONS About Modus Therapeutics Modus is a Swedish biotechnology company that is developing its proprietary polysaccharide sevuparin as a potential treatment for several major healthcare needs including sepsis, endotoxemia, severe malaria and other disorders with severe systemic inf
Slide 6: Modus pipeline
STATEMENT OF OPERATIONS Modus pipeline INDICATION DEVELOPMENT Preclinical Phase Ia Phase Ib Phase IIa Phase IIb Phase III Sepsis Modus Sepsis/Septic chock Planning Phase IIa Anemia* Modus Anemia chronic inflammation/kidney disease Before start Phase Malaria Collaboration** Severa malaria (ongoing st
Slide 7: Preclinical research suggests that Sevuparin
STATEMENT OF OPERATIONS These robust results from preclinical cellular and ani- mal models as well as human subjects demonstrate sevuparin’s ability to suppress hepcidin at clinically safe dose levels and provide strong evidence of its ability to modulate hepcidin expression. In addition, data from
Slide 8: Completed studies support phase 2 development in sepsis and anemia in chronic disease
STATEMENT OF OPERATIONS Completed studies support phase 2- Plasma hepcidin development in sepsis and anemia in decreased to 30-50% of baseline values chronic disease in the presence of Sevuparin, with maximal Sevuparin has been shown to be safe and tolerable with single and multiple suppression betw
Slide 9: Market overview
STATEMENT OF OPERATIONS Market overview With sevuparin, Modus primarily target three challanging indications - sepsis, anemia and severe malaria. Sevuparin has significant potential within the markets for these indication, which are mainly driven by the significant medical need and the increasing gl
Slide 10: Anemia in chronic kidney disease
STATEMENT OF OPERATIONS Anemia in chronic kidney disease Anemia is a global health issue affecting approxi- mately 2.3 billion people, which represents 25% of the world’s population. The most common form of anemia is iron deficiency anemia, impacting nearly one billion individuals. Chronic kidney di
Slide 11: Severe malaria
STATEMENT OF OPERATIONS Severe malaria Severe malaria is a rapidly progressing and serious condition resembling sepsis, primarily affecting young children, with a mortality rate of 10-20%. While available standard treatments are effective given time to start working, there is a lack of an adjuvant t
Slide 12: Development of profit and financial position
FINANCIAL REPORT Development of profit and financial position Second quarter First half-year Operating profit/loss Operating profit/loss Operating loss for the period April-June 2024 Operating loss for the period January-June amounted to TSEK 4 804 (4 365). The costs 2024 amounted to TSEK 8 003 (10
Slide 13: Important events during and after the quarter
FINANCIAL REPORT Important events during authorization to the board, for a period that does not extend past the date of the next Important events after the quarter annual general meeting, on one or several the end of the quarter occasions, with or without pre-emptive rights for the shareholders, to
Slide 14: Other disclosures
FINANCIAL REPORT Other disclosures Ownership structure (370). The loss for the period amounted to cash and cash equivalents amounted to SEK At the end of the fourth quarter, there were TSEK 3 366 (3 974). The company’s net sales 11,8 million. 946 shareholders in Modus Therapeutics consist of invoice
Slide 15: Financial report: risks and uncertainties
FINANCIAL REPORT There are no guarantees that the required ca- The Board monitors the evolvement of the pital can be raised to finance the developme- crises closely and Modus is working intensi- nt on favorable terms, or that the capital can vely to minimize the impact of these crises. be procured a
Slide 16: Consolidated summary income statement
FINANCIAL REPORT Consolidated summary income statement 2024 2023 2024 2023 2023 TSEK Apr 1 - Jun 30 Apr 1 - Jun 30 Jan 1 - Jun 30 Jan 1 - Jun 30 Jan 1 - Dec 31 Net sales - - - - - Research and development costs -2 911 -2 297 -4 396 -6 253 -8 482 Administration costs -1 898 -1 991 -3 599 -3 814 -7 83
Slide 17: Consolidated summary balance sheet
FINANCIAL REPORT Consolidated summary balance sheet 2024 2023 2023 TSEK Jun 30 Jun 30 Dec 31 Assets Fixed assets Other financial fixed assets 51 50 51 Total fixed assets 51 50 51 Current assets Other receivables 497 34 930 Cash equivalents 11 971 4 822 19 060 Total current assets 12 468 5 556 19 990
Slide 18: Consolidated change in shareholder's equity in summary
FINANCIAL REPORT Consolidated change in shareholder’s equity in summary 2024 2023 2024 2023 2023 TSEK Apr 1 - Jun 30 Apr 1 - Jun 30 Jan 1 - Jun 30 Jan 1 - Jun 30 Jan 1 - Dec 31 Opening balance equity 14 576 -8 625 17 681 -2 585 -2 585 Profit/loss for the period -4 738 -4 695 -7 843 -10 735 -17 897 T
Slide 19: Consolidated cash flow statement in summary
FINANCIAL REPORT Consolidated cash flow statement in summary 2024 2023 2024 2023 2023 TSEK Apr 1 - Jun 30 Apr 1 - Jun 30 Jan 1 - Jun 30 Jan 1 - Jun 30 Jan 1 - Dec 31 Operating activities Operating profit/loss -4 804 -4 365 -8 003 -10 173 -16 401 Interest received 66 - 160 - 3 Interest paid - - - - -
Slide 20: Parent company income statement in summary
FINANCIAL REPORT Parent company income statement in summary 2024 2023 2024 2023 2023 TSEK Apr 1 - Jun 30 Apr 1 - Jun 30 Jan 1 - Jun 30 Jan 1 - Jun 30 Jan 1 - Dec 31 Net sales 185 185 370 370 740 Research and development costs -65 -3334 -766 -681 -1 419 Administration costs -1 884 -1 584 -3 129 -3 09
Slide 21: Parent company balance sheet in summary
FINANCIAL REPORT Parent company balance sheet in summary 2024 2023 2023 TSEK Jun 30 Jun 30 Dec 31 Assets Non-current assets Financial assets 70 051 70 050 70 051 Total non-current assets 70 051 70 050 70 051 Current assets Other receivables 554 634 762 Cash equivalents 11 289 4 004 18 381 Total curr
Slide 22: Notes to the financial reports in summary
FINANCIAL REPORT Notes to the financial reports in summary Note 1 | Accounting principles earnings. Modus Therapeutics Holding AB’s consoli- Note 3 | Incentive program Note 4 | Equity dated accounts have been prepared in At the Annual General Meeting on May 3, The share capital of the Parent Company
Slide 23: Financial calendar and signatures
FINANCIAL REPORT Financial calendar Signatures Interim Report Q3 2024 The Board of Directors and the CEO provide their assurance that this interim | November 20th, 2024 report provides an accurate view of the operations, position and earning of the group and the parent company, and that it also desc
Slide 24: Quarterly overview and definitions
FINANCIAL REPORT Quarterly overview 2024 2023 2022 THE GROUP Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Net sales, TSEK - - - - - - - - Operating profit, TSEK -4 804 -3 199 -3 771 -2 456 -4 365 -5 808 -9 121 -2 829 Equity/Asset ratio, % 79% 91% 88% -311% -238% -117% -23% 35% Cash equivalents, TSEK 11 971 15 395 19 060
Slide 25: Contact
CONTACT Olof Palmes gata 29 IV John Öhd, CEO 111 22 Stockholm +46(0)70-766 80 97 Sweden john.ohd@modustx.com +46(0)8-502 492 53 Claes Lindblad, CFO & IR responsible ir@modustx.com +46(0)70-246 75 54 www.modustx.com ir@modustx.com 25
Modus Therapeutics Holding — Q2 2024 Earnings Presentation on 6ix